Xoma | XOMA - Gross Profit On Sales

Stock Price
41.75
Daily Change
-0.25 -0.60%
Monthly
5.40%
Yearly
54.69%
Q2 Forecast
40.91

Xoma reported 992K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Agenus USD 34.2M 4.61M Dec/2025
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Ardelyx USD 114.37M 8.02M Dec/2025
aTyr Pharma USD 190K 15.57M Sep/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Celldex Therapeutics USD 121K 609K Dec/2025
Curis USD 1.14M 8.86M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 11.04B 1.24B Mar/2026
Prothena USD 21K 2.39M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Xoma 992K 846K Jun/2024